EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

CSPC Pharmaceutical Group Ltd (1093) fair value: what the stock is really worth

We calculate from audited financials what CSPC Pharmaceutical Group Ltd is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · HK · ISIN HK1093012172

CP Broad data Sep 18, 2026

CSPC Pharmaceutical Group Ltd

1093 · HK

NeutralQuality growthThe stock looks roughly fairly valued with average quality.

·Fair value HK$9.74 · Fairly valued (+9%)
✓Quality 65/100
!Weak Growth (revenue 5y +1.4 %/yr)
✓Solidly profitable · 12.8% net margin (TTM)
✓Low debt · generates free cash flow
·2.69% dividend yield
!Mixed vs. peers (7/15)
!Moderate moat 52/100
!Insider activity 40/100
Watch CSPC Pharmaceutical Group Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$11.06 HK$4.13 Fair Value HK$9.74 May 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 18, 2026.

How to read this chart

60‑month range HK$4.13 – HK$11.06 · fair‑value band HK$6.82 – HK$12.65 · the HK$8.93 price screens below the HK$9.74 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 18, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments.

Show more

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent infection induced by chemotherapy; and Keaili for breast cancer. It also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, the company provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food products; and healthcare services. It has a strategic collaboration with AstraZeneca PLC to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications and multiple therapies for obesity and type 2 diabetes. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.

Stock analysis

CSPC Pharmaceutical Group Ltd (1093) currently trades at HK$8.93, while our model-based Fair Value estimate is HK$9.74, implying the stock looks roughly 8.3% fairly valued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of HK$8.71 per share, and 6 of the 26 models we run sit above the HK$8.93 price.

Bear case: the Asset-Based group reads lowest at HK$1.95, and 20 of the 26 models stay below the price. Evidence for this calculation is high.

Scenario range: HK$6.82 (bear) to HK$12.65 (bull), the price of HK$8.93 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 65/100 (solid quality), in the Healthcare sector.

Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.

CSPC Pharmaceutical Group Ltd reported revenue of 25.3B CNY in FY2025 versus 27.4B CNY in FY2021, a compound −1.9%/yr. Reported net income was 3.8B CNY in FY2025, compounding −9.0%/yr from FY2021.

Key figures

Market cap HK$102B (≈ $13.0B) · P/E ratio 18.6 · P/S ratio 2.77 · EPS (TTM) HK$0.3170 · Dividend yield 2.7% · Net margin 14.9% · Return on equity 9.6% · Return on assets (EBIT) 14.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).

What moves the price

The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.

The share trades about 22% below its 52-week high and 34% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at 9%, 1093 screens cheaper than that median.

Fair Value models

Bear HK$6.82 Fair Value HK$9.74 Bull HK$12.65
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (HK$0.0557 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF HK$5.27 HK$9.60 HK$17.52 77
Growth DCF HK$5.19 HK$9.04 HK$15.81 76
5Y EBITDA Exit HK$5.12 HK$8.97 HK$13.92 74
All 26 models by family
DCF Models
FCF DCF HK$5.27 HK$9.60 HK$17.52 77
Owner Earnings HK$4.39 HK$7.91 HK$14.36 73
5Y Revenue Exit HK$4.14 HK$6.87 HK$10.64 71
5Y EBITDA Exit HK$5.12 HK$8.97 HK$13.92 74
5Y P/E Exit HK$5.53 HK$9.86 HK$14.96 69
10Y Revenue Exit HK$4.36 HK$7.14 HK$11.53 65
10Y EBITDA Exit HK$5.13 HK$8.71 HK$14.37 66
10Y P/E Exit HK$5.41 HK$9.37 HK$15.27 62
Earnings-Based
Graham-Dodd HK$2.25 HK$11.76 HK$16.27 63
Lynch FV HK$3.22 HK$4.61 HK$5.99 61
PEG = 1.0 HK$3.22 HK$4.61 HK$5.99 57
EPV HK$3.01 HK$3.42 HK$3.78 74
Dividend Discount
Gordon GGM HK$1.96 HK$4.07 HK$6.46 66
DDM Multi-Stage HK$1.96 HK$3.43 HK$4.27 66
Multiples
P/E Multiple HK$5.47 HK$7.29 HK$9.12 63
P/S Multiple HK$4.23 HK$5.64 HK$7.05 58
P/B Multiple HK$4.23 HK$5.64 HK$7.05 55
EV/EBIT HK$4.86 HK$6.30 HK$7.74 66
EV/EBITDA HK$5.36 HK$6.97 HK$8.58 67
EV/Revenue HK$3.62 HK$4.94 HK$6.27 54
Asset-Based
NCAV (Graham) HK$1.46 HK$1.95 HK$2.91 54
Growth DCF
Growth DCF HK$5.19 HK$9.04 HK$15.81 76
Rev-Margin DCF HK$4.14 HK$6.80 HK$10.38 71
Economic Profit
Residual Income HK$2.67 HK$3.05 HK$5.04 74
ROIC Compounder HK$3.07 HK$4.05 HK$5.03 72
Growth Earnings
Growth-Adj P/E HK$4.93 HK$7.04 HK$9.16 67

Open the full fair value analysis →

Notify me when 1093 reaches fair value

Put 1093 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 65/100

Of which business quality 67 · Market factors (momentum, volatility) 48

Profitability 53
Margins and returns on capital today
Quality Growth 10
Are margins and returns improving?
Cashflow 69
Earnings quality: real cash, not paper profit
Fin. Strength 89
Balance sheet, leverage, solvency risk
Investment 76
Disciplined investing over empire-building
Low Volatility 56
Calm price path (market factor)
Momentum 50
Price trend over the last 3–12 months (market factor)
52W Momentum 34
Distance to the 52-week high (market factor)
Net Issuance 99
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
−14.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.4%
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.8%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−1.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−4.1%
Dividend (yield on the price)2.7%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−4% vs 11%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.22% → 15%

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+10.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+6.5%
Yearly sales growth analysts expect, extended to five years.
Forecast 2026 (sales)+40.8%
Forecast 2027 (sales)−1.4%
Projected 2028 (sales)−0.9%
Projected 2029 (sales)−0.5%
Projected 2030 (sales)−0.1%

Watch 1093, get fair value alerts →

Compare CSPC Pharmaceutical Group Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 73 stocks

Beats the industry median on 6/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 65 · Above median
Fair Value upside −26% · Below median
Profitability
Return on equity (TTM) 10% · Below median
Return on assets 5% · Below median
Net margin (TTM) 13% · Below median
Operating margin (TTM) 15% · Below median
Growth and dividend
Revenue growth −8% · Bottom 25%
Dividend yield (TTM) 2.7% · Above median

Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper

P/E (TTM) 18.6× · Cheaper than median
P/B 2.79× · Cheaper than median
P/S (TTM) 3.63× · Pricier than median
P/FCF 3.0× · Cheaper than median
EV/EBITDA 18.8× · Pricier than median
PEG 0.33× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)45 · sector 9
FUTURE (revenue growth)0 · sector 27
PAST (return on equity)38 · sector 49
HEALTH (low debt)100 · sector 94
DIVIDEND (yield)54 · sector 41

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Eli Lilly and Company LLY $1,136 $778.94 −31%
Johnson & Johnson, JNJ $267.20 $169.04 −37%
AbbVie Inc ABBV $263.04 $259.66 −1%
Roche Holding RO CHF 369.80 CHF 306.54 −17%
Merck & Co MRK €124.22 €101.89 −18%
Novartis AG NVS $137.16 $138.70 +1%
Novo Nordisk A/S NOVOB kr 272.60 kr 409.46 +50%
Amgen Inc AMGN $375.65 $413.22 +10%
Gilead Sciences, Inc GILD $146.30 $198.51 +36%
Pfizer Inc PFE $27.55 $20.39 −26%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

CSPC Pharmaceutical Group Ltd · Fair Value
HK$9.74 +8%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "CSPC Pharmaceutical Group Ltd Fair Value". https://www.fairvalue-calculator.com/stock/1093

Frequently asked questions

Is CSPC Pharmaceutical Group Ltd (1093) overvalued or undervalued?
As of Sep 18, 2026, our model estimates a fair value of HK$9.74 versus a price of HK$8.93, about +9% upside (fairly valued).
What is the fair value of 1093?
Our model-based fair value for CSPC Pharmaceutical Group Ltd is HK$9.74 (as of Sep 18, 2026), built from audited fundamentals. The current price: HK$8.93.
What is the quality score of 1093?
CSPC Pharmaceutical Group Ltd has a Quality Score of 65/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CSPC Pharmaceutical Group Ltd (1093)?
Our model-based price target is the fair value of HK$9.74 (as of Sep 18, 2026) from 26 valuation models. Cautious scenario HK$6.82, optimistic scenario HK$12.65. It is a calculation from audited fundamentals, not an analyst target.
What is the CSPC Pharmaceutical Group Ltd stock forecast for 2026?
Our models put fair value at HK$9.74, about +9% upside versus a price of HK$8.93 (fairly valued). Cautious scenario HK$6.82, optimistic scenario HK$12.65. The calculation is refreshed regularly with new filings.
What is the revenue of CSPC Pharmaceutical Group Ltd (1093)?
CSPC Pharmaceutical Group Ltd reported trailing-twelve-month revenue of about HK$25.5B (latest available figure, as of Sep 18, 2026).
Does CSPC Pharmaceutical Group Ltd pay a dividend?
CSPC Pharmaceutical Group Ltd currently shows a dividend yield of about 2.69% relative to its recent price (as of Sep 18, 2026).
What growth is priced into CSPC Pharmaceutical Group Ltd (1093)?
For today's price to be fair in a discounted-cash-flow model, CSPC Pharmaceutical Group Ltd would have to grow free cash flow by +10.8 % per year for five years (discount rate 9.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +1.4 % per year. As of Sep 18, 2026.
What discount rate (WACC) does the fair value of 1093 use?
Our models discount CSPC Pharmaceutical Group Ltd at 9.1 %: a base by market capitalisation (large), damped by beta 0.73, country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For CSPC Pharmaceutical Group Ltd that is +10.8 % per year a year over ten years, using the same discount rate (9.1 %) and the same formula as our fair value.
How much growth has CSPC Pharmaceutical Group Ltd (1093) delivered so far?
Over the past 5 years revenue at CSPC Pharmaceutical Group Ltd grew +1.4 % a year. The price currently implies +10.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of CSPC Pharmaceutical Group Ltd (1093) growing?
The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into CSPC Pharmaceutical Group Ltd (+10.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of CSPC Pharmaceutical Group Ltd (1093)?
The free-cash-flow yield on the price is 3.91 %: that much free cash flow CSPC Pharmaceutical Group Ltd produces per unit of market value. When it exceeds the discount rate of our models (9.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of CSPC Pharmaceutical Group Ltd (1093)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CSPC Pharmaceutical Group Ltd it is HK$9.74 per share (as of Sep 18, 2026), against a price of HK$8.93. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is CSPC Pharmaceutical Group Ltd stock overvalued or undervalued in 2026?
As of Sep 18, 2026, 1093 trades below its calculated fair value: price HK$8.93, fair value HK$9.74, a gap of about +9% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1093?
No. The price is what the market pays today (HK$8.93); the fair value is what the company's own numbers justify (HK$9.74). For CSPC Pharmaceutical Group Ltd the two are HK$0.8050 per share apart. That gap is exactly why we show both numbers side by side.
How much is CSPC Pharmaceutical Group Ltd worth?
The market values CSPC Pharmaceutical Group Ltd at about HK$102B (market capitalisation, as of Sep 18, 2026). Per share that is HK$8.93; our models calculate a fair value of HK$9.74 per share.
What do the bullish and bearish scenarios say about 1093?
Our models span a range for CSPC Pharmaceutical Group Ltd: cautious scenario HK$6.82, base HK$9.74, optimistic HK$12.65 per share (as of Sep 18, 2026, price HK$8.93). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1093?
CSPC Pharmaceutical Group Ltd trades at a price-to-earnings ratio of 18.6 (as of Sep 18, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$9.74 is built from several models across several years. Other multiples: PEG 0.3, P/B 2.8, P/S 3.6, EV/EBITDA 18.8.
What is the PEG ratio of 1093?
The PEG ratio of CSPC Pharmaceutical Group Ltd is 0.33 (P/E divided by earnings growth, as of Sep 18, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of CSPC Pharmaceutical Group Ltd (1093)?
Balance-sheet figures for CSPC Pharmaceutical Group Ltd (as of Sep 18, 2026): return on equity 9.6%. They feed the Quality Score of 65/100, which measures business quality independently of the share price.
How far is 1093 from its 52-week high?
CSPC Pharmaceutical Group Ltd trades at HK$8.93, about 22% below its 52-week high of HK$11.45 and 34% above the low of HK$6.64 (as of Sep 18, 2026). Distance from the high says nothing about value: that is what the fair value of HK$9.74 is for.
Which stocks are comparable to CSPC Pharmaceutical Group Ltd?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CSPC Pharmaceutical Group Ltd stock attractive at the current price?
The data as of Sep 18, 2026: price HK$8.93, calculated fair value HK$9.74 (+9%), Quality Score 65/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1093 calculated?
We run CSPC Pharmaceutical Group Ltd through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$9.74, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 16.1 % above its aggregate fair value. CSPC Pharmaceutical Group Ltd currently trades 9 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CSPC Pharmaceutical Group Ltd (1093)?
The closing price on Sep 18, 2026 was HK$8.93. Our model-based fair value is HK$9.74, about +9% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CSPC Pharmaceutical Group Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (HK$6.82 to HK$12.65) leaves room in how you read the outcome.
Where does the earnings growth of CSPC Pharmaceutical Group Ltd (1093) come from?
Earnings per share at CSPC Pharmaceutical Group Ltd grew +13.9 % a year from 2014 to 2025. Broken into its drivers: revenue per share +12.6 %, EBIT margin +0.6 %, tax rate +0.1 %, residual (interest, one-offs) +0.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of CSPC Pharmaceutical Group Ltd

How large is the market capitalisation of CSPC Pharmaceutical Group Ltd (1093)?
The market capitalisation of CSPC Pharmaceutical Group Ltd is HK$102B (≈ $13.0B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CSPC Pharmaceutical Group Ltd (1093)?
The price-to-sales ratio of CSPC Pharmaceutical Group Ltd is 2.77 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of CSPC Pharmaceutical Group Ltd (1093)?
Earnings per share at CSPC Pharmaceutical Group Ltd are HK$0.3170 (price ÷ EPS = P/E 18.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of CSPC Pharmaceutical Group Ltd (1093)?
The dividend yield of CSPC Pharmaceutical Group Ltd is 2.7% (payout 75.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of CSPC Pharmaceutical Group Ltd (1093)?
The net margin of CSPC Pharmaceutical Group Ltd is 14.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of CSPC Pharmaceutical Group Ltd (1093)?
The return on equity (ROE) of CSPC Pharmaceutical Group Ltd is 9.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CSPC Pharmaceutical Group Ltd (1093)?
On an EBIT basis the return on assets of CSPC Pharmaceutical Group Ltd is 14.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CSPC Pharmaceutical Group Ltd (1093)?
The operating margin of CSPC Pharmaceutical Group Ltd is 15.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CSPC Pharmaceutical Group Ltd (1093)?
Revenue at CSPC Pharmaceutical Group Ltd is growing −7.8% versus a year earlier (3y avg −7.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at CSPC Pharmaceutical Group Ltd (1093)?
Earnings per share at CSPC Pharmaceutical Group Ltd are growing −41.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does CSPC Pharmaceutical Group Ltd (1093) hold?
CSPC Pharmaceutical Group Ltd holds more cash than debt, HK$5.5B net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch CSPC Pharmaceutical Group Ltd in the live analysis

One click puts CSPC Pharmaceutical Group Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.